

PRODUCT INFORMATION & MANUAL

Human TGF beta 1 Platinum ELISA

BMS249/4 / BMS249/4TEN

Enzyme-linked Immunosorbent Assay for
quantitative detection of human TGF beta 1.
For research use only.
Not for diagnostic or therapeutic procedures.



Human TGF beta 1 Platinum ELISA

North America

Technical Support:

Research Products:
888.810.6168
858.642.2058
tech@eBioscience.com

Clinical Products:
877.726.8559
858.642.2058
tech@eBioscience.com

Customer Service:

888.999.1371
858.642.2058
info@eBioscience.com

Fax:

858.642.2046

Europe/International*

Technical Support:

+43 1 796 40 40-120
tech@eBioscience.com

Customer Service:

+43 1 796 40 40-305
info@eBioscience.com

Fax:

+43 1 796 40 40-400



Bender MedSystems GmbH
Campus Vienna Biocenter 2
1030 Vienna, Austria
www.eBioscience.com

* Customers outside North America and Europe
may contact their eBioscience distributor listed on
our website at www.eBioscience.com/distributors.

TABLE OF CONTENTS

1	Intended Use	3
2	Summary	3
3	Principles of the Test	7
4	Reagents Provided	9
5	Storage Instructions – ELISA Kit	11
6	Specimen Collection and Storage Instructions	11
7	Materials Required But Not Provided	12
8	Precautions for Use	13
9	Preparation of Reagents	15
10	Test Protocol	19
11	Calculation of Results	24
12	Limitations	27
13	Performance Characteristics	28
14	Ordering Information	34
15	Reagent Preparation Summary	34
16	Test Protocol Summary	36

1 Intended Use

The human TGF beta 1 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human TGF beta 1. **The human TGF beta 1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2 Summary

Transforming growth factor beta (TGF beta) is a pleiotropic cytokine that exhibits a broad spectrum of biological and regulatory effects on the cellular and organism level. It plays a critical role in cellular growth, development, differentiation, proliferation, extracellular matrix (ECM) synthesis and degradation, control of mesenchymal-epithelial interactions during embryogenesis, immune modulation, apoptosis, cell cycle progression, angiogenesis, adhesion and migration and leukocyte chemotaxis. It has both tumor suppressive and tumor promoting activities and is highly regulated at all levels (e.g.: mRNA turnover, latent protein activation or post-translational modifications).

TGF beta is the first recognized protein of at least 40 of the TGF beta superfamily of structurally related cytokines.

Three isoforms (TGF beta 1-3) have been described in mammals. (Each isoform is encoded by a unique gene on different chromosomes. All bind to the same receptors.) They are synthesized by most cell types and tissues. Cells of the immune system mainly express TGF beta 1.

The initially sequestered, inactive LTGF beta (latent TGF beta) requires activation (cleavage and dissociation of its LAP (latency associated peptide) region) before it can exert biological activity. LTGF beta can also be bound to LTB (latent TGF beta binding protein) to form a large latent complex (LLC). TGF beta forms homodimers, and its subunits of 12.5 kDa each are bound via disulphide bridges.

TGF beta signal transduction is mediated via the TGF beta receptors Type II and I, phosphorylation and conformational changes, followed by different pathways:

SMAD (- pathway: TGF beta recruitment finally leads to phosphorylation of receptor-regulated SMADs (R-SMADs = SMAD 2, 3) and binding of common SMAD (coSMAD = SMAD 4). The R-SMAD/ coSMAD complex enters the nucleus and interacts with a number of transcription factors, coactivators and corepressors.

TGF beta induces MAPK- and MAP/ERK kinase dependent signal transduction (JNK/MAPK-, JNK/SPAK-, p38-, ERK1/2 - pathway) and the NF- κ B – pathway. TGF beta mediates cell cycle growth arrest via the phosphoinositide 3-kinase/Akt pathway.

TGF beta signaling is highly regulated e.g. via interaction with inhibitory SMADs (I-SMADs = SMAD 6, 7) or binding of the E3-ubiquitin ligases Smurf1 and Smurf2 or/and coreceptors.

TGF beta 1 is the key mediator in the pathophysiology of tissue repair and human fibrogenesis: balance between production and degradation of type I collagen, and fibrosis and scarring in organ and tissue.

TGF beta 1 exhibits important immunoregulatory features of partially adverse character: TGF beta 1 inhibits B and T cell proliferation, differentiation and antibody production as well as maturation and activation of macrophages. It inhibits activity of NK cells and lymphokine activated killer cells and blocks production of cytokines. TGF beta 1 promotes Treg cell differentiation resulting in IL-10/TGF beta 1 production and Th1 cell and Th2 cell suppression.

TGF beta 1 was recently shown to promote Th17 development in the presence of IL-6 or IL-21 in mice and probably plays a role in human Th17 development together with IL-1 beta, IL-21 and IL-23. In this context TGF beta 1 is involved in induction and mediation of proinflammatory and allergic responses.

Cancer: TGF beta 1 is overexpressed in a high percentage of human tumors (e.g.: breast, prostate, renal cell, pancreatic, ovarian, cervical and gastric cancer and melanoma, non-hodgkin's lymphoma, multiple myeloma) and has been correlated with poor prognosis.

TGF beta 1 acts as a tumor suppressor (particularly in the early stage of carcinogenesis) and as a tumor promoter (namely, tumor progression, invasion and metastasis). Malignant cells secrete TGF beta 1, suppressing antitumor immune responses and creating immune tolerance. Mutations in the TGF beta 1 signaling pathway (e.g.: loss of cell surface receptors, decreased SMAD expression) render tumors refractory to growth inhibitory and apoptotic effects of TGF beta 1.

Autoimmune diseases: TGF beta 1 is functionally connected to major immune system abnormalities such as Systemic Lupus Erythematosus (SLE). In Multiple Sclerosis (MS) up-regulation of TGF beta 1 seems to correlate with a benign course and minor disability of MS. In autoimmune hepatitis (AIH) up-regulated serum TGF beta 1 has been observed. Pathological remodeling of connective tissue in systemic

sclerosis (SSc) is attributed to the activation of the TGF beta 1/ SMAD pathway. In mice, TGF beta 1 gene transfer to the colon leads to intestinal fibrosis and serves as a mouse model for Crohn's disease (CD).

Liver: Increased TGF beta 1 expression was shown in hepatic fibrosis of chronic liver diseases (chronic hepatitis, alcoholic cirrhosis). Hepatitis C virus upregulates TGF beta 1 transcription in the liver and elevates circulating TGF beta 1 levels. Disrupting TGF beta 1 synthesis and/or signaling pathways prevents scar formation in experimental liver fibrosis. Removal of excess collagen after cessation of liver disease is regulated by TGF beta 1.

Kidney diseases: Glomerulonephritis and diabetic nephropathy due to excessive accumulation of ECM within the mesangium of the glomeruli is attributed to high TGF beta 1 levels. Urinary TGF beta 1 levels of patients with these diseases are elevated.

Diabetes: Expression levels and kinase activities of components of the TGF beta signaling pathway are altered in diseases of the pancreas. Low TGF beta levels in patients with Type I diabetes may contribute to a lack of immunosuppression and to disease propagation and maintenance.

Cardiovascular Diseases: TGF beta 1 is anti-atherogenic and atheroprotective, but loses its protective role and exhibits pathogenic effects in chronic disease. Increased TGF beta 1 levels were found in atherosclerotic clinical specimens. Dilated, ischaemic and hypertrophic cardiomyopathies are associated with high TGF beta 1 levels. TGF beta 1 induces endothelial cells to undergo EndMT (endothelial-mesenchymal transition), which contributes to the progression of cardiac fibrosis associated with chronic heart disease. Decreased serum levels of TGF beta 1 in sepsis and acute stroke patients may reflect the changing immunological-inflammatory status of these patients. Remodeling after myocardial infarction is attributed to TGF beta 1. An upregulation of TGF beta 1 in the central nervous system after ischemia-induced brain damage has been described. A neuroprotective role of TGF beta 1 against ischemia-induced neuronal cell death was found.

Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Cystic fibrosis (CF): TGF beta 1 plays an important role in chronic airway diseases, particularly in airway remodeling. Increased TGF beta 1 levels have been described in patients with severe asthma and airway eosinophilic inflammation, and have been correlated to the degree of sub-epithelial fibrosis. In mouse models decreased TGF beta 1 lead to

reduced peribronchial fibrosis, airway smooth muscle proliferation and mucus production. TGF beta 1 was shown to induce apoptosis in airway epithelial cells. Integrin mediated local activation of TGF beta is critical for the development of pulmonary edema in acute lung injury.

Others: In Alzheimers Disease (AD) increased TGF beta 1 immunoreactivity and TGF beta 1 mRNA levels correlate with beta-amyloid deposition in damaged cerebral blood vessels. A number of proinflammatory chemokines including TGF beta 1 are consistently elevated in brains of autistic patients. Decreased TGF beta 1 serum levels were described for patients with acute malaria. In periodontitis increased TGF beta 1 levels were measured in gingival crevicular fluid. Patients with duchenne muscular dystrophy showed elevated TGF beta 1 expression levels and fibrosis. Increased TGF beta signaling events in scleroderma fibroblasts were shown. TGF beta 1 is a potent stimulator of chondrocyte matrix production versus tissue fibrosis and thus might play an important role in bone metabolism (Osteoarthritis).

For literature update refer to **www.eBioscience.com**

3 Principles of the Test

An anti-human TGF beta 1 coating antibody is adsorbed onto microwells.

Human TGF beta 1 present in the sample or standard binds to antibodies adsorbed to the microwells.

A biotin-conjugated anti-human TGF beta 1 antibody is added and binds to human TGF beta 1 captured by the first antibody.

Following incubation unbound biotin-conjugated anti-human TGF beta 1 antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human TGF beta 1 antibody.

Figure 1




Figure 2




Figure 3






Figure 4




Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

Figure 5



A coloured product is formed in proportion to the amount of human TGF beta 1 present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human TGF beta 1 standard dilutions and human TGF beta 1 sample concentration determined.

Figure 6



4 Reagents Provided

4.1 Reagents for human TGF beta 1 ELISA BMS249/4 (96 tests)

- 1 aluminium pouch with a **Microwell Plate coated** with monoclonal antibody to human TGF beta 1
- 1 vial (120 µl) **Biotin-Conjugate** anti-human TGF beta 1 polyclonal antibody
- 1 vial (150 µl) **Streptavidin-HRP**
- 2 vials human TGF beta 1 **Standard** lyophilized, 4 ng/ml upon reconstitution
- 1 vial (5 ml) **Assay Buffer Concentrate** 20x (PBS with 1% Tween 20, 10% BSA)
- 1 bottle (50 ml) **Wash Buffer Concentrate** 20x (PBS with 1% Tween 20)
- 1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (15 ml) **Stop Solution** (1M Phosphoric acid)
- 6 **Adhesive Films**

4.2 Reagents for human TGF beta 1 ELISA BMS249/4TEN (10x96 tests)

- 10 aluminium pouches with a **Microwell Plate coated** with monoclonal antibody to human TGF beta 1
- 10 vials (120 µl) **Biotin-Conjugate** anti-human TGF beta 1 polyclonal antibody
- 10 vials (150 µl) **Streptavidin-HRP**
- 10 vials human TGF beta 1 **Standard** lyophilized, 4 ng/ml upon reconstitution
- 5 vials (5 ml) **Assay Buffer Concentrate 20x**
(PBS with 1% Tween 20, 10% BSA)
- 7 bottles (50 ml) **Wash Buffer Concentrate 20x**
(PBS with 1% Tween 20)
- 10 vials (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (100 ml) **Stop Solution** (1M Phosphoric acid)
- 30 **Adhesive Films**

5 Storage Instructions – ELISA Kit

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C).

Expiry of the kit and reagents is stated on labels. Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6 Specimen Collection and Storage Instructions

Cell culture supernatant*, serum and plasma (EDTA, citrate, heparin) were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human TGF beta 1. If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 0).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

* Pay attention to a possibly elevated blank signal in cell culture supernatant samples containing serum components (e.g. FCS), due to latent TGF beta levels in animal serum.

7 Materials Required But Not Provided

- 1N NaOH and 1N HCL are needed to run the test
- 5 ml and 10 ml graduated pipettes
- 5 μ l to 1000 μ l adjustable single channel micropipettes with disposable tips
- 50 μ l to 300 μ l adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microplate shaker
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8 Precautions for Use

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.

- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9 Preparation of Reagents

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure.

If crystals have formed in the **Buffer Concentrates**, warm them gently until they have completely dissolved.

9.1 Wash Buffer (1x)

Pour entire contents (50 ml) of the **Wash Buffer Concentrate (20x)** into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water.

Mix gently to avoid foaming.

Transfer to a clean wash bottle and store at 2° to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

9.2 Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate (20x)** into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2° to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

9.3 Biotin-Conjugate

Please note that the Biotin-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated **Biotin-Conjugate** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

9.4 Streptavidin-HRP

Please note that the Streptavidin-HRP should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated **Streptavidin-HRP** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

9.5 Human TGF beta 1 Standard

Reconstitute **human TGF beta 1 standard** by addition of distilled water. Reconstitution volume is stated on the label of the standard vial. Swirl or mix gently to insure complete and homogeneous solubilization (concentration of reconstituted standard = 4 ng/ml). Allow the standard to reconstitute for 10-30 minutes. Mix well prior to making dilutions.

After usage remaining standard cannot be stored and has to be discarded.

Standard dilutions can be prepared directly on the microwell plate (see 10.d) or alternatively in tubes (see 9.5.1).

9.5.1 External Standard Dilution

Label 7 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6, S7

Then prepare 1:2 serial dilutions for the standard curve as follows:
Pipette 225 µl of Assay Buffer (1x) into each tube.


Pipette 225 µl of reconstituted standard (concentration of standard = 4 ng/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 2 ng/ml).

Pipette 225 µl of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer.

Repeat serial dilutions 5 more times thus creating the points of the standard curve (see Figure 7).

Assay Buffer (1x) serves as blank.


Figure 7



10 Test Protocol

- a. Prepare your samples before starting the test procedure. Dilute serum, plasma and cell culture supernatant samples 1:10 with Assay Buffer (1x) according to the following scheme:
20 µl sample + 180 µl Assay Buffer (1x)
Add 20 µl 1N HCl (see 7) to 200 µl prediluted sample, mix and incubate for 1 hour at room temperature.
Neutralize by addition of 20 µl 1N NaOH (see 7). **Vortex!**
- b. Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2°-8°C sealed tightly.
- c. Wash the microwell strips twice with approximately 400 µl **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells.
After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry.**
- d. **Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes – see 9.5.1):
Add 100 µl of Assay Buffer (1x) in duplicate to all **standard wells**. Pipette 100 µl of prepared **standard** (see Preparation of Standard 9.5, concentration = 4000 pg/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 2000 pg/ml), and transfer 100 µl to wells B1 and B2, respectively (see Figure 8). Take care not to scratch the inner surface of the microwells. Continue this procedure 5 times, creating two rows of human TGF beta 1 standard dilutions ranging from 2000 to 31 pg/ml. Discard 100 µl of the contents from the last microwells (G1, G2) used.

Figure 8



In case of an **external standard dilution** (see 9.5.1), pipette 100 µl of these standard dilutions (S1 - S7) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (2000 pg/ml)	Standard 1 (2000 pg/ml)	Sample 1	Sample 1
B	Standard 2 (1000 pg/ml)	Standard 2 (1000 pg/ml)	Sample 2	Sample 2
C	Standard 3 (500 pg/ml)	Standard 3 (500 pg/ml)	Sample 3	Sample 3
D	Standard 4 (250 pg/ml)	Standard 4 (250 pg/ml)	Sample 4	Sample 4
E	Standard 5 (125 pg/ml)	Standard 5 (125 pg/ml)	Sample 5	Sample 5
F	Standard 6 (63 pg/ml)	Standard 6 (63 pg/ml)	Sample 6	Sample 6
G	Standard 7 (31 pg/ml)	Standard 7 (31 pg/ml)	Sample 7	Sample 7
H	Blank	Blank	Sample 8	Sample 8

- e. Add 100 μ l of **Assay Buffer (1x)** in duplicate to the **blank wells**.
- f. Add 60 μ l of **Assay Buffer (1x)** to the **sample wells**.
- g. Add 40 μ l of each pretreated **sample** in duplicate to the **sample wells**. **(It is absolutely necessary to vortex the samples!)**
- h. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 2 hours, on a microplate shaker set at 400 rpm. **(Shaking is absolutely necessary for an optimal test performance.)**
- i. Prepare **Biotin-Conjugate** (see Preparation of Biotin-Conjugate 9.3).
- j. Remove adhesive film and empty wells. **Wash** microwell strips 5 times according to point c. of the test protocol. Proceed immediately to the next step.
- k. Add 100 μ l of **Biotin-Conjugate** to all wells.
- l. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 1 hour, on a microplate shaker set at 400 rpm. **(Shaking is absolutely necessary for an optimal test performance.)**
- m. Prepare **Streptavidin-HRP** (refer to Preparation of Streptavidin-HRP 9.4).
- n. Remove adhesive film and empty wells. **Wash** microwell strips 5 times according to point c. of the test protocol. Proceed immediately to the next step.
- o. Add 100 μ l of diluted **Streptavidin-HRP** to all wells, including the blank wells.
- p. Cover with an adhesive film and incubate at room temperature (18° to 25°C) for 1 hour, on a microplate shaker set at 400 rpm. **(Shaking is absolutely necessary for an optimal test performance.)**
- q. Remove adhesive film and empty wells. **Wash** microwell strips 5 times according to point c. of the test protocol. Proceed immediately to the next step.
- r. Pipette 100 μ l of **TMB Substrate Solution** to all wells.

- s. Incubate the microwell strips at room temperature (18° to 25°C) for **about 30 min**. Avoid direct exposure to intense light.

The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable. Determination of the ideal time period for colour development has to be done individually for each assay.

It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.9 – 0.95.

- t. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2 - 8°C in the dark.
- u. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

11 Calculation of Results

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human TGF beta 1 concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human TGF beta 1 for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human TGF beta 1 concentration.
- **If instructions in this protocol have been followed, samples have been diluted 1:30 (20 µl sample + 180 µl Assay Buffer (1x) + 20µl 1N HCl + 20µl 1N NaOH and 40 µl pretreated sample + 60 µl Assay Buffer (1x)) and the concentration read from the standard curve must be multiplied by the dilution factor (x 30).**
- **Calculation of samples with a concentration exceeding standard 1 may result in incorrect, low human TGF beta 1 levels. Such samples require further external predilution according to expected human TGF beta 1 values with Assay Buffer (1x) in order to precisely quantitate the actual human TGF beta 1 level.**
- It is suggested that each testing facility establishes a control sample of known human TGF beta 1 concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 9. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 9

Representative standard curve for human TGF beta 1 ELISA. Human TGF beta 1 was diluted in serial 2-fold steps in Assay Buffer (1x). Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human TGF beta 1 ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

Standard	Human TGF beta 1 Concentration (pg/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V. (%)
1	2000	3.227 3.068	3.148	2.5%
2	1000	1.373 1.402	1.387	1.0%
3	500	0.587 0.592	0.590	0.4%
4	250	0.300 0.326	0.313	4.1%
5	125	0.178 0.166	0.172	3.5%
6	63	0.109 0.114	0.112	2.0%
7	31	0.078 0.086	0.082	4.7%
Blank	0	0.052 0.050	0.051	2.0%

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12 Limitations

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13 Performance Characteristics

13.1 Sensitivity

The limit of detection of human TGF beta 1 defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 8.6 pg/ml (mean of 6 independent assays).

13.2 Reproducibility

13.2.1 Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human TGF beta 1. 2 standard curves were run on each plate. Data below show the mean human TGF beta 1 concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 3.2%.

Table 3

The mean human TGF beta 1 concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human TGF beta 1 Concentration (pg/ml)	Coefficient of Variation (%)
1	1	38237.8	3.6%
	2	39660.8	2.6%
	3	39216.3	0.8%
2	1	20394.0	1.4%
	2	21289.3	3.0%
	3	21513.2	2.5%
3	1	22408.0	2.1%
	2	23957.9	3.4%
	3	24232.4	1.8%
4	1	18901.8	1.7%
	2	19649.6	3.0%
	3	21305.9	8.3%
5	1	4428.0	2.9%
	2	4723.3	2.8%
	3	4670.0	7.1%
6	1	4764.2	3.2%
	2	5063.1	2.5%
	3	4703.2	4.6%
7	1	3357.8	2.2%
	2	3887.2	3.2%
	3	3212.4	5.5%
8	1	4159.7	2.5%
	2	4455.3	2.1%
	3	3924.2	4.5%

13.2.2 Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum plasma samples containing different concentrations of human TGF beta 1. 2 standard curves were run on each plate. Data below show the mean human TGF beta 1 concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 4.9%.

Table 4

The mean human TGF beta 1 concentration and the coefficient of variation of each sample

Sample	Mean Human TGF beta 1 Concentration (pg/ml)	Coefficient of Variation (%)
1	39038.3	1.9 %
2	21065.5	2.8 %
3	23532.8	4.2 %
4	19952.4	6.2 %
5	4607.1	3.4 %
6	4843.5	4.0 %
7	3485.8	10.2 %
8	4179.7	6.4 %

13.3 Spike Recovery

The spike recovery was evaluated by spiking 3 levels of human TGF beta 1 into serum, plasma and cell culture supernatant. Recoveries were determined with 4 replicates each.

The amount of endogenous human TGF beta 1 in unspiked samples was subtracted from the spike values.

For recovery data see Table 5.

Table 5

Sample matrix	Spike high		Spike medium		Spike low	
	Mean (%)	Range (%)	Mean (%)	Range (%)	Mean (%)	Range (%)
Serum	85	83 - 87	97	96 - 99	96	92 - 101
Plasma (EDTA)	90	80 - 114	84	74 - 97	82	78 - 85
Plasma (citrate)	108	96 - 122	92	88 - 95	92	88 - 96
Plasma (heparin)	110	98 - 119	87	87 - 110	93	87 - 100
Cell culture supernatant	87	85 - 89	85	84 - 85	95	92 - 98

13.4 Dilution Parallelism

Serum, plasma and cell culture supernatant samples with different levels of human TGF beta 1 were analysed at serial 2 fold dilutions with 4 replicates each (except for CCS with only 1 replicate). For recovery data see Table 6.

Table 6

Sample matrix	Recovery of Exp. Val.		
	Dilution	Mean (%)	Range (%)
Serum	1:60	103	93 – 108
	1:120	112	81 – 128
	1:240	97	75 – 113
Plasma (EDTA)	1:60	119	114 – 128
	1:120	129	118 – 142
	1:240	138	127 – 150
Plasma (citrate)	1:60	108	102 – 113
	1:120	119	110 – 128
	1:240	130	112 – 139
Plasma (heparin)	1:60	121	112 – 134
	1:120	130	119 – 150
	1:240	126	120 - 131
Cell culture supernatant	1:60	95	-
	1:120	103	-
	1:240	118	-

13.5 Sample Stability

13.5.1 Freeze-Thaw Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human TGF beta 1 levels determined. There was no significant loss of human TGF beta 1 immunoreactivity detected by freezing and thawing.

13.5.2 Storage Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 2-8°C and room temperature (RT), and the human TGF beta 1 level determined after 24 h. There was no significant loss of human TGF beta 1 immunoreactivity detected during storage under above conditions.

13.6 Specificity

The assay detects both natural and recombinant human TGF beta 1. The cross reactivity of TGF beta 2 and TGF beta 3, and of TNF beta, IL-8, IL-6, IL-2, TNF alpha, IL-1 beta, IL-4, IFN gamma, IL-12p70, IL-5 and IL-10 was evaluated by spiking these proteins at physiologically relevant concentrations into serum. There was no cross reactivity detected.

13.7 Expected Values

A panel of samples from randomly selected apparently healthy donors (males and females) was tested for human TGF beta 1. For detected human TGF beta 1 levels see Table 7.

Table 7

Sample Matrix	Number of Samples Evaluated	Range (pg/ml)	Mean (pg/ml)	Standard Deviation (pg/ml)
Serum	16	5222 - 13731	6723	1978
Plasma (EDTA)	40	0 – 2644	729	389
Plasma (Citrate)	40	908 – 3378	1726	578
Plasma (Heparin)	40	0 – 377	46	96

14 Ordering Information

North America

Technical Support:

Research Products:
888.810.6168
858.642.2058
tech@eBioscience.com

Clinical Products:
877.726.8559
858.642.2058
tech@eBioscience.com

Customer Service:

888.999.1371
858.642.2058
info@eBioscience.com

Fax:

858.642.2046

Europe/International*

Technical Support:

+43 1 796 40 40-120
tech@eBioscience.com

Customer Service:

+43 1 796 40 40-305
info@eBioscience.com

Fax:

+43 1 796 40 40-400



Bender MedSystems GmbH
Campus Vienna Biocenter 2
1030 Vienna, Austria
www.eBioscience.com

* Customers outside North America and Europe may contact their eBioscience distributor listed on our web site at www.eBioscience.com/distributors.

15 Reagent Preparation Summary

15.1 Wash Buffer (1x)

Add **Wash Buffer Concentrate 20x** (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

15.2 Assay Buffer (1x)

Add **Assay Buffer Concentrate 20x** (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

15.3 Biotin-Conjugate

Make a 1:100 dilution of **Biotin-Conjugate** in Assay Buffer (1x):

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

15.4 Streptavidin-HRP

Make a 1:100 dilution of **Streptavidin-HRP** in Assay Buffer (1x):

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

15.5 Human TGF beta 1 Standard

Reconstitute lyophilized **human TGF beta 1 standard** with distilled water. (Reconstitution volume is stated on the label of the standard vial.).

16 Test Protocol Summary

1. Pretreatment: 1:10 predilution (20 µl sample + 180 µl Assay Buffer (1x)), add 20 µl 1N HCl (see 7) to 200 µl prediluted sample, mix and incubate for 1 hour at room temperature, add 20 µl 1N NaOH (see 7) **(Vortex!)**
2. Determine the number of microwell strips required.
3. Wash microwell strips twice with Wash Buffer.
4. Standard dilution on the microwell plate: Add 100 µl Assay Buffer (1x), in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells. Alternatively external standard dilution in tubes (see 9.5.1): Pipette 100 µl of these standard dilutions in the microwell strips.
5. Add 100 µl Assay Buffer (1x), in duplicate, to the blank wells.
6. Add 60 µl Assay Buffer (1x) to sample wells.
7. Add 40 µl sample in duplicate, to designated sample wells. **(It is absolutely necessary to vortex the samples!)**
8. Cover microwell strips and incubate 2 hours at room temperature (Shaking is absolutely necessary for an optimal test performance.)
9. Prepare Biotin-Conjugate.
10. Empty and wash microwell strips 5 times with Wash Buffer.
11. Add 100 µl Biotin-Conjugate to all wells.
12. Cover microwell strips and incubate 1 hour at room temperature. (Shaking is absolutely necessary for an optimal test performance.)
13. Prepare Streptavidin-HRP.
14. Empty and wash microwell strips 5 times with Wash Buffer.
15. Add 100 µl diluted Streptavidin-HRP to all wells.
16. Cover microwell strips and incubate 1 hour at room temperature. (Shaking is absolutely necessary for an optimal test performance.)
17. Empty and wash microwell strips 5 times with Wash Buffer.
18. Add 100 µl of TMB Substrate Solution to all wells.
19. Incubate the microwell strips for **about 30 minutes** at room temperature (18° to 25°C).
20. Add 100 µl Stop Solution to all wells.
21. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:30 (20 µl sample + 180 µl Assay Buffer (1x) + 20µl 1N HCl + 20µl 1N NaOH and 40 µl pretreated sample + 60 µl Assay Buffer (1x)), the concentration read from the standard curve must be multiplied by the dilution factor (x 30).